“Scientific Superintelligence”
Legal name: Lila Sciences, Inc. · Not publicly traded (private)
Headquarters: Cambridge, MA, USA
Lila Sciences is building the world's first scientific superintelligence platform and fully autonomous labs for life, chemical, and materials sciences. Founded in Flagship Pioneering's labs in 2023 and unveiled in March 2025, the company combines proprietary AI foundation models with robotic AI Science Factories that autonomously generate hypotheses, design experiments, run them, and learn from results in real time.
Pipeline and financial figures on this page are curated for the Clari product experience and are not a substitute for SEC filings, regulatory records, or trial registry data. This is not medical or investment advice. Verify material facts with primary sources.
Lila Sciences is building the world's first scientific superintelligence platform and fully autonomous labs for life, chemical, and materials sciences. Founded in Flagship Pioneering's labs in 2023 and unveiled in March 2025, the company combines proprietary AI foundation models with robotic AI Science Factories that autonomously generate hypotheses, design experiments, run them, and learn from results in real time. The platform spans therapeutics (proteins, antibodies, mRNA, small molecules, cell therapies), advanced materials, energy, and chemical catalysis.
Teams and mission starters combine the curated case study, your profile text, and a live sponsor-matched slice from the same ClinicalTrials.gov batch as the trial list for Lila Sciences. The first listed mission in the first team always mirrors that registry batch.
Sponsor search: Lila Sciences
Live ClinicalTrials.gov API pass for configured sponsor string "Lila Sciences" returned 0 studies in this batch. Confirm the lead sponsor name on the registry and try related sponsor strings if needed.
AI-Driven Autonomous Scientific Discovery
Closed-loop autonomous labs where AI agents generate hypotheses, design experimental protocols, operate laboratory equipment, capture multimodal data, and update models with results in real time. A human scientist or partner uploads a research objective, and the platform analyzes proprietary and public datasets to drive the full experimental cycle.
All programs across therapeutic areas
Retrieved from ClinicalTrials.gov
No trials returned from ClinicalTrials.gov at this time.
Search directly on ClinicalTrials.govLive from PubMed / NCBI
Collaborations amplifying pipeline reach
Timeline visualization requires programs with clinical trial data.
Powered by ClariTrial
Select a question to ask
Lila is an AI and autonomous lab platform. The emerging intel squad is built for nontraditional, fast-moving competitive sets (AI native labs, foundation models, CRO disrupters). Your profile describes AI and automation-heavy R&D; emerging intel fits non-obvious competitors.
Starter missions
Company: Lila Sciences. The live Clari company page used sponsor search string "Lila Sciences" and received 0 studies in the current API batch. Propose 2 to 3 alternative lead or collaborator sponsor strings to try on ClinicalTrials.gov, and explain how partner-led trials could appear under a different sponsor. Compare with the curated pipeline on this page and note likely reasons for a registry gap. Not medical or investment advice.
Map the competitive landscape for AI-native autonomous R&D and lab-in-the-loop platforms: compare positioning of Lila Sciences to Recursion, Isomorphic, Anduril-style biotech lab stacks, and large pharma internal AI units. Separate proven partnerships from press-only claims.
Argue the strategic tradeoffs for Lila as a services and platform business versus building owned therapeutic pipelines, including typical biotech margin and defensibility issues. No investment recommendation; analytical framing only.
For Flagship-style unveilings, partner weeks, and technical deep-dives where transcript-style analysis matters.
Starter missions
Prepare a question set for a diligence or partnering conversation with an AI-lab company like Lila: data rights, model validation, IP on generated molecules, and how success is measured in client programs.
Lila is Cambridge, MA. Local ecosystem context (Flagship, talent, infrastructure) is often part of the story. Headquarters in the Boston or Cambridge area; the geographic team complements local peer tracking.
Starter missions
Summarize the Greater Boston AI-for-biology and lab-automation cluster relevant to Lila: notable companies, shared investors, and typical hiring or site footprint patterns. Emphasize public information only.
No individual clinical programs publicly disclosed. Platform designed and validated therapeutic molecules including novel antibodies and protein therapeutics. Revenue model is project-based R&D services for pharma partners, with potential for proprietary pipeline spin-outs.
Materials science programs including ultra-stable metals and novel catalysts. Demonstrates cross-domain versatility of the platform beyond therapeutics.
Changes to the relative abundance of amyloid-beta (Aβ) peptides are hallmarks of Alzheimer's disease. Induced pluripotent stem cell (iPSC)-derived neurons offer a physiological model of Aβ production. We employed unbiased, data-driven analyses to investigate combinations of Aβ peptides as Alzheimer's disease biomarkers and the relative contribution of peptides to Alzheimer's disease pathogenesis. We measured Aβ37, Aβ38, Aβ40, Aβ42 and Aβ43 in 10 iPSC-neuronal cultures from PSEN1 mutation carriers. We combined these data with published cell model data and used linear weighted combinations to (i) distinguish Alzheimer's disease from controls, and (ii) predict age-at-onset for PSEN1 mutations. Data-driven approaches distinguished Aβ42 and Aβ43 from shorter peptides, providing unbiased evidence for a greater association of Aβ42 and Aβ43 to disease pathogenesis, compared with shorter peptides (Aβ37, Aβ38 and Aβ40). Weighted linear combinations of Aβ peptides outperform Aβ42/40 and provide insights into relative peptide contribution as biomarkers. A representative weighted composite value ratio (wCVR) derived from all data, balancing both disease classification and age-at-onset prediction, was ( 21 ⋅ A β 37 + 10 ⋅ A β 38 + 69 ⋅ A β 40 ) /   ( 94 ⋅ A β 42 + 6 ⋅ A β 43 ) . This work suggests a practical non-parametric harmonization approach to employing Aβ ratios as biomarkers for Alzheimer's disease, from multiple sites and assays. Building on this foundation, we applied a new model using weighted composite value ratios, which outperform existing biomarkers across all tasks. This underscores the value of integrating multiple peptides and assigning optimized weightings. The study confirms the association of Aβ42 and Aβ43 with Alzheimer's disease pathogenesis in a data-driven manner. Peptide weights further provide mechanistic insights into the relative contribution of each peptide to disease, such as a greater contribution of Aβ37 compared to Aβ38. The algorithm used herein can be further refined to improve biomarkers for Alzheimer's disease.
AI-Driven Autonomous Scientific Discovery
AI Competitive Analysis
Compare Lila Sciences against 5 competitors across technology, pipeline, funding, and strategic positioning
Lila was founded in Flagship's labs in 2023. Flagship led the seed round and remains a core investor. Part of the Flagship ecosystem alongside Moderna, Generate Biomedicines, and others.
AWS is the preferred cloud provider for Flagship companies including Lila. Provides cloud credits, technical support, and AI capabilities to accelerate scientific platforms.
NVIDIA Ventures participated in the October 2025 Series A extension, reflecting alignment on GPU-accelerated scientific computing.
Company history and program progress